| 5.97 0.34 (6.04%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.08  |
1-year : | 8.28 |
| Resists | First : | 6.07 |
Second : | 7.08 |
| Pivot price | 4.48 |
|||
| Supports | First : | 4.04 |
Second : | 2.79 |
| MAs | MA(5) : | 5 |
MA(20) : | 4.15 |
| MA(100) : | 3.54 |
MA(250) : | 4.55  |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 82.8 |
D(3) : | 67.9 |
| RSI | RSI(14): 79.3 |
|||
| 52-week | High : | 8.62 | Low : | 2.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NTRB ] has closed above the upper band by 0.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 284.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.08 - 6.1 | 6.1 - 6.13 |
| Low: | 5.12 - 5.14 | 5.14 - 5.16 |
| Close: | 5.93 - 5.97 | 5.97 - 6.02 |
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Fri, 04 Sep 2026
NutriBand Inc. 3Q 2026: Revenue $437514 EPS $(0.07) — 10-Q Summary - TradingView
Fri, 04 Sep 2026
NutriBand (NTRB) cuts cash burn as sales slip - Stock Titan
Fri, 04 Sep 2026
NTRB 10-Q Filings - Nutriband Inc SEC 10-Q - Stock Titan
Sat, 15 Aug 2026
Nutriband Inc. (NTRB) Advances 3.45% to $3.30, Testing Key Resistance at $3.46 - Buy Signal Reports - vinanet.vn
Sat, 15 Aug 2026
Nutriband Inc. (NTRB) Advances 3.45% to $3.30, Testing Key Resistance at $3.46 - Factor Valuation - dars.gov.et
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 56.8 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 169 (K) |
| Shares Short P.Month | 153 (K) |
| EPS | -2.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | -289.5 % |
| Return on Assets (ttm) | -78.2 % |
| Return on Equity (ttm) | -145.8 % |
| Qtrly Rev. Growth | -35.1 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -2.34 |
| PEG Ratio | 0 |
| Price to Book value | 12.18 |
| Price to Sales | 40.33 |
| Price to Cash Flow | -16.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|